Sasi George’s Post

AI is set to reshape healthcare! Medtech startup Qure.ai has secured $65 Mn (INR 543 Cr) in a Series D funding round, co-led by Lightspeed Venture Partners and 360 ONE Asset Management. The round also saw participation from Merck Global Health Innovation Fund, Kae Capital, and existing investors Novo Holdings, Health Quad, and TeamFund. This funding will be used to: 1. Expand in the US and other global markets 2. Enhance its GenAI foundation models 3. Support future acquisitions Founded in 2016 by Prashant Warier, Qure.ai leverages AI to revolutionize medical imaging diagnostics, detecting critical conditions such as brain trauma and chest diseases from X-rays, CT scans, and MRIs in record time. The impact of AI in healthcare is immense, addressing bottlenecks in diagnostics, drug discovery, patient management, and even surgical robotics. It is evident that India's medtech sector is booming! Startups like SigTuple and Visit Health raised significant funds, and Innovaccer is in talks for a $200 Mn-$250 Mn funding round,Last month. SOurce - https://lnkd.in/dekh2qSs Prashant Warier Kudos to the team Dr Abhilash O V Manishkumar Jain Hardik Solanki Dr Ishan Yadav M Nagarajan #MedTech #AI #HealthcareInnovation #DigitalHealth #QureAI #Startups #Funding #Tech

Bengaluru-based neurotech startup Nexstem has raised $3.5 million in a funding round led by investors such as InfoEdge, Zupee, Smile Group , and Gruhas . This investment will enable Nexstem to scale its groundbreaking brain-computer interface (BCI) technology, expand its IP portfolio, and accelerate global growth, especially in American and European markets. Nexstem’s flagship BCI platform, Instinct, uses AI to process biosignals, allowing seamless human-device interactions. Co-founder Siddhant Dangi stated, “With this funding, we are advancing the BCI ecosystem, harnessing complex biosignal data to create innovative solutions across sectors.” By reducing costs, Nexstem democratizes access to neurotech, paving the way for sci-fi-like applications in longevity and telepathy. With the BCI market forecasted to hit $400 billion in the US alone, Nexstem aims to launch new technologies and expand into defense and consumer markets. #Nexstem #Neurotech #BCI #BrainComputerInterface #DeepTech #VentureCapital #Innovation #Technology #StartupFunding #AI #TechNews #SiddhantDangi #Management #Creativity #Futurism #Startups #Marketing #SocialMedia #SocialNetworking #Motivation

𝗡𝗲𝘄 𝗔𝗜 𝗠𝗲𝗱𝘁𝗲𝗰𝗵 & 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗼𝗿 𝘁𝗼 𝗹𝗮𝘂𝗻𝗰𝗵... ✨ The Johns Hopkins University, CareFirst BlueCross BlueShield, and Techstars are launching an #accelerator focused on healthcare #AI. The 13-week program will invest in up to 12 startups per cohort, with investments up to $120,000 per startup. 💡 Techstars has a solid history in #healthtech with over 600 companies, including Ovia Health, Owlet Baby Care, PillPack (acquired by Amazon), and Ginger (merged with Headspace). 💡 In H1 2024, #AI-driven startups have already attracted substantial #venturecapital interest, with the sector seeing a 40% increase in funding compared to 2023 💡 According to Rock Health, 38% of all #digitalhealth funding in H1 went to AI-focused startups 💡 In H1 2024 #AI startups in #Medtech, #Biotech and #Healthtech have raised over $2.8 Billion, marking a significant rise from H1 2023 Read the full article below: ⤵ https://lnkd.in/eZeQCsPu #medtech #healthtech #biotech #artificialintelligence #AI #startupaccelerator #startup #vc #venturefunding #executivesearch #medicaldevice #recruitment #healthcare

Start-ups in the U.S. are closing down at an alarming rate. In Q1 of 2024 alone, 254 venture-backed start-ups filed for bankruptcy; a rate 7 times higher than in 2019. A major reason behind this trend seems to be the massive investments pouring into AI start-ups, which attracted billions in funding but are now struggling to deliver on their promises. Is there a lesson here for the biotech sector as it navigates its own innovation trends? Take Tome Biosciences, for example. Despite raising over $200 million last year for its gene-editing advancements, but with no clinical programs. The company is now scaling back operations and laying off almost its entire workforce due to changing investor sentiment and market pressures. The lesson here for biotech? Securing funding is not enough. Quickly translating innovations into clinical realities while market sentiment and trends favor their technology is crucial for biotech companies. #startups #investment #biotech #AI

𝗪𝗵𝗼 𝗪𝗶𝗹𝗹 𝗙𝘂𝗻𝗱 𝗦𝗲𝗲𝗱 𝗥𝗼𝘂𝗻𝗱𝘀 𝗳𝗼𝗿 𝗠𝗲𝗱𝗧𝗲𝗰𝗵 𝗦𝘁𝗮𝗿𝘁𝘂𝗽𝘀? 𝗔𝗻𝗱 𝗪𝗵𝗲𝗻 𝗪𝗶𝗹𝗹 𝗜𝘁 𝗚𝗲𝘁 𝗘𝗮𝘀𝗶𝗲𝗿? The struggle for early-stage MedTech startups to secure seed funding is real—and I've seen it firsthand. Just last week, I read an insightful article in Nature Biotechnology (link in comments) that highlighted the current state of financing in Biotech. The findings are strikingly relevant to MedTech as well. Here’s the summary: • 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗰𝗮𝗽𝗶𝘁𝗮𝗹 𝗶𝘀 𝗳𝗹𝗼𝘄𝗶𝗻𝗴—but primarily into Series A, B, and C rounds for more mature startups with experienced leadership and proven technologies in clinical stages (later-stage development). • 𝗦𝗲𝗲𝗱 𝗳𝘂𝗻𝗱𝗶𝗻𝗴, 𝗵𝗼𝘄𝗲𝘃𝗲𝗿, 𝗶𝘀 𝘀𝗰𝗮𝗿𝗰𝗲. Investors are hesitant to back startups in the pre-clinical stages, where core technologies still need significant de-risking (early-stage development). This has created a polarized environment of "haves" and "have-nots." 𝗪𝗵𝘆 𝘁𝗵𝗲 𝗰𝗼𝗻𝘀𝗲𝗿𝘃𝗮𝘁𝗶𝘃𝗲 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵? Higher interest rates and an abundance of attractive, lower-risk clinical-stage companies emerging from the pandemic's peak years mean investors can choose less risky opportunities at appealing valuations. 𝗦𝗼, 𝘄𝗵𝗲𝗻 𝘄𝗶𝗹𝗹 𝗲𝗮𝗿𝗹𝘆-𝘀𝘁𝗮𝗴𝗲 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝘁𝘁𝗿𝗮𝗰𝘁 𝗺𝗼𝗿𝗲 𝗳𝘂𝗻𝗱𝗶𝗻𝗴? It’s hard to say. But one thing is clear: For the Biotech and MedTech sectors to keep growing, we’ll need fresh, innovative technologies. And that can only happen if we start fueling early-stage startups again. Let’s hope that day comes sooner rather than later. #Medtech #Biotech #MedicalDevices #Innovation

#GenAI #Healthcare #Startups Attract Record #Investments Amidst Overall #Funding Decline Despite a significant drop in overall healthcare startup funding, investments in #generativeartificialintelligence (GenAI) healthcare startups have surged dramatically! According to GlobalData Plc, these #startups saw investments rise from $81 million in January 2022 to a whopping $439 million by June 2024. 💡 Key Insights: 🔹 GenAI #VentureCapital Deals: $447 million in H1 2024 🔹 Overall Healthcare Startup Funding: Declined by 65% over the same period 🗣️ Expert Insight: Charlton Media Group's Healthcare Asia quotes Manish Dixit, Practice Head for #DisruptiveTech at #GlobalData, highlights that this surge is driven by GenAI's potential to enhance #diagnosticprecision, advance operations, and improve patient outcomes. "AI-assisted decision-making is becoming a cornerstone for healthcare companies aiming to reduce operational costs and optimize their services," Dixit says. 👉 Why Invest in GenAI Healthcare Startups? 🔹 Revolutionize Diagnostics: Enhances precision and accuracy. 🔹 Optimize Operations: Streamlines processes and reduces costs. 🔹 Improve Patient Outcomes: Provides better, more personalized care. 🔍 Dive deeper into this transformative trend and stay ahead in the healthcare innovation race! #Decodethefuture #GlobalData Archi Dasgupta GlobalData Technology Prathyusha Paruchuri Pranjali Mujumdar

Public Exits Are Getting More Feasible In The Medtech Space – MedCity News - MedCity News #PublicExits #MedTech #Feasibility Public Exits Are Getting More Feasible In The Medtech Space A recent trend in the healthcare IT industry is the increasing feasibility of public exits for companies in the medtech space. This trend is driven by various factors such as capital availability and market demand. #MarketTrends #InvestmentOpportunities Market Trends and Investment Opportunities With the rise of digital health technologies, there is a growing demand for innovative solutions in the healthcare industry. This has created new investment opportunities for companies in the medtech sector looking to go public. #RegulatoryEnvironment #Compliance Navigating the Regulatory Environment and Ensuring Compliance One of the key challenges for medtech companies seeking ai.mediformatica.com #medtech #startups #this #report #pitchbook #cost #healthcare #medcity #news #outdated #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3MdOLkZ)

𝐍𝐞𝐰𝐬 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐟𝐨𝐫 𝟑𝟎𝐭𝐡 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟒 1. 𝐆𝐥𝐨𝐛𝐚𝐥 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐀𝐈 𝐬𝐭𝐚𝐫𝐭𝐮𝐩 Qure.ai 𝐫𝐚𝐢𝐬𝐞𝐬 $𝟔𝟓 𝐌𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝐒𝐞𝐫𝐢𝐞𝐬 𝐃 𝐫𝐨𝐮𝐧𝐝 𝐥𝐞𝐝 𝐛𝐲 Lightspeed 𝐚𝐧𝐝 360 ONE Asset   AI-driven healthcare startup Qure.ai raised $65 million in Series D funding led by Lightspeed and 360 ONE Asset, with participation from 𝐌𝐞𝐫𝐜𝐤 𝐆𝐥𝐨𝐛𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐅𝐮𝐧𝐝, Kae Capital, and others. The funds will accelerate expansion into the US, develop AI models, enhance technology, and support strategic acquisitions. Qure.ai operates in over 90 countries, offering AI solutions for critical disease management.   2. Whatfix 𝐛𝐚𝐠𝐬 $𝟏𝟐𝟓 𝐌𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝐒𝐞𝐫𝐢𝐞𝐬 𝐄 𝐫𝐨𝐮𝐧𝐝 𝐥𝐞𝐝 𝐛𝐲 Warburg Pincus LLC   SaaS major Whatfix raised $125 million in Series E funding led by Warburg Pincus LLC, with participation from 𝐒𝐨𝐟𝐭𝐁𝐚𝐧𝐤 𝐕𝐢𝐬𝐢𝐨𝐧 𝐅𝐮𝐧𝐝 𝟐. The funds will accelerate growth, drive strategic acquisitions, and expand globally, including in the Middle East and Southeast Asia. Whatfix aims to enhance its Digital Adoption Platforms (DAP) offerings and continue growing in the US, Europe, and APAC regions. 3. Ahammune Biosciences Pvt. Ltd. 𝐁𝐢𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐛𝐚𝐠𝐬 $𝟓 𝐌𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝐒𝐞𝐫𝐢𝐞𝐬 𝐀 𝐟𝐮𝐧𝐝𝐢𝐧𝐠 Ahammune Biosciences Pvt. Ltd. raised $5 million in Series A funding led by pi Ventures, with participation from 𝐂𝐚𝐩𝐢𝐭𝐚𝐥𝟐𝐁, Colossa Ventures, and others. The funds will support Phase II clinical trials for its vitiligo drug candidate, expand its patent portfolio, and advance research for immune-mediated skin diseases. Vitiligo is a chronic condition marked by recurring white patches on the skin. 4. 𝐌𝐮𝐤𝐞𝐬𝐡 𝐁𝐚𝐧𝐬𝐚𝐥’𝐬 𝐥𝐚𝐭𝐞𝐬𝐭 𝐯𝐞𝐧𝐭𝐮𝐫𝐞 Nurix 𝐀𝐈 𝐛𝐚𝐠𝐬 $𝟐𝟕.𝟓 𝐌𝐢𝐥𝐥𝐢𝐨𝐧 𝐟𝐫𝐨𝐦 General Catalyst, Accel   Nurix 𝐀𝐈, founded by 𝐌𝐮𝐤𝐞𝐬𝐡 𝐁𝐚𝐧𝐬𝐚𝐥, raised $27.5 million in seed-Series A funding co-led by General Catalyst and Accel, with 𝐌𝐞𝐫𝐚𝐤𝐢 𝐋𝐚𝐛𝐬 participating. The company specializes in custom AI agents with human-like voice and reasoning abilities to boost enterprise productivity. Nurix AI aims to enhance voice and reasoning capabilities for high-accuracy, low-latency solutions powered by generative AI for global businesses. 𝐅𝐨𝐥𝐥𝐨𝐰 Corporate Valuations 𝐟𝐨𝐫 𝐦𝐨𝐫𝐞 𝐬𝐮𝐜𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 #newhighlight #newsupdates #Startups #Investment #Growth #acquisition #Funding #StartupFunding #Investmen #funds #EquityFunding #Valuation #StartupNews #StartupInvestment #VentureFunding #ValuationServices #BusinessValuation

🙋♀️ Do you believe in the promise of #DigitalHealth to improve #patient outcomes and #reducecost in #drugdevelopment? 💊 📲 Do you want to know how to bridge the gap between #pharma and digital #health #startups working on these innovative solutions? 💥 PharmStars knows how to bring startups and #biopharma together to bridge the pharma/startup gap! Our 10-week #accelerator program is designed to prepare startups for more productive engagements with pharma, teaching them what they need to know. 🚀 🌏 PharmStars is a virtual #accelerator, open to digital health startups from around the world because healthcare #innovation has no bounds 🙌 and happens anywhere. Our Fall accelerator will focus on "Digital Innovations in #Clinical Trials." Learn more and apply (deadline is July 15!) 👉 👉 👉 www.PharmStars.com #transformation #healthcare #biotech #biopharma #entrepreneurs #digitaltransformation #digitalinnovation, #remotemonitoring #patientexperience #clinicaltrials #digital #innovation #digitalhealth #startups #virtualtrials #accelerator #acceleratorprogram #datacollection #RemotePatientMonitoring #RPM #datamanagement

In 2024, biotech and healthcare startups are leading U.S. Series A funding, securing $5.6 billion in 110 rounds, which is 53% of all Series A investments. Although overall Series A funding has increased slightly from last year, it remains below 2022 and significantly lower than 2021. These startups are getting fewer but larger funding rounds, dominating the biggest deals. Many biotech companies are going public after Series A or B rounds, bypassing additional funding rounds. This shift leaves less Series A funding for other sectors, especially impacting startups in generative AI and other fields. Seed-funded companies now face tougher competition for Series A investment.